Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Deals

Ningbo Sanxing Medical Electric Files HKEX Prospectus with Dual Business Model in Power Equipment and Rehabilitation Services

Fineline Cube Jun 15, 2026

Ningbo Sanxing Medical Electric Co., Ltd. announced it has filed its prospectus for listing on...

Company Drug

Gritpharma Secures NMPA Approval for Doxylamine as China’s First Novel Short-Term Insomnia Treatment

Fineline Cube Jun 15, 2026

Nanjing Gritpharma Co., Ltd. announced it has received marketing approval from China’s National Medical Products...

Company Deals Hospital Medical Device

Baheal Pharma Partners with Jinan Junxin Hospital to Launch ZAP-X Precision Radiosurgery Center

Fineline Cube Jun 15, 2026

Baheal Pharma Group (SHE: 301015) announced a strategic partnership with Jinan Junxin Cancer Hospital to...

Company Deals

Lannacheng Biotechnology Files HKEX Prospectus with 13-Candidate Radiopharmaceutical Pipeline

Fineline Cube Jun 15, 2026

Yantai Lannacheng Biotechnology Co., Ltd. announced it has filed its prospectus for listing on the...

Company Legal / IP

Harbour BioMed Wins $20.2 Million Patent Verdict Against Amgen in Delaware Court

Fineline Cube Jun 15, 2026

Harbour BioMed (HKG: 2142) announced that a jury in the U.S. District Court for the...

Company Drug

Sichuan Biokin’s Iza-Bren Becomes World’s First EGFR×HER3 Bispecific ADC with NDA Accepted by China’s NMPA

Fineline Cube Jun 15, 2026

Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the new drug application (NDA) for...

Company Deals

SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health

Fineline Cube Jun 15, 2026

SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with...

Company Deals

Simcere Pharmaceutical Partners with Stanford University to Develop First-in-Class IPF Therapy

Fineline Cube Jun 15, 2026

Simcere Pharmaceutical Group (HKG: 2096) announced a collaborative research agreement with Stanford University School of...

Company Drug

Novo Nordisk to Fully Launch Sogroya in China This Summer for Pediatric Growth Hormone Deficiency

Fineline Cube Jun 15, 2026

Novo Nordisk (NYSE: NVO) announced that its long-acting growth hormone injection Sogroya (somapacitan) will be...

Company Deals

Medtronic Completes $550 Million Acquisition of Scientia Vascular to Strengthen Neurovascular Portfolio

Fineline Cube Jun 15, 2026

Medtronic (NYSE: MDT) announced on June 12, 2026 the completion of its acquisition of Scientia...

Company Drug

Sanofi’s Tzield Receives FDA Approval to Preserve Insulin Production in Recently Diagnosed Type 1 Diabetes

Fineline Cube Jun 15, 2026

Sanofi (NASDAQ: SNY) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated...

Company Medical Device

Roche’s VENTANA PTEN Assay Receives FDA Approval as First Companion Diagnostic for AstraZeneca’s Truqap in Prostate Cancer

Fineline Cube Jun 15, 2026

Roche Holding AG (SWX: ROP, OTCMKTS: RHHBY) announced that the VENTANA PTEN (SP218) RxDx Assay...

Company Drug

Jazz Pharmaceuticals Reports Phase 3 LAGOON Trial Misses Primary Endpoint for Zepzelca in Relapsed Small Cell Lung Cancer

Fineline Cube Jun 15, 2026

Jazz Pharmaceuticals (NASDAQ: JAZZ) announced on June 12, 2026 that the Phase 3 LAGOON trial,...

Company Drug

AstraZeneca’s Truqap Receives FDA Approval as First Targeted Therapy for PTEN-Deficient Prostate Cancer

Fineline Cube Jun 15, 2026

AstraZeneca plc (NYSE: AZN) announced that the U.S. Food and Drug Administration (FDA) has approved...

Company Deals

Micot Pharmaceutical Successfully Lists on Hong Kong Stock Exchange with HK$1.22 Billion IPO

Fineline Cube Jun 15, 2026

Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2355) announced its successful listing on the Hong...

Company Drug

Merck Secures FDA Approval for Keytruda-Welireg Combination as Adjuvant Therapy in High-Risk Kidney Cancer

Fineline Cube Jun 15, 2026

Merck & Co., Inc. (MSD; NYSE: MRK) announced that the U.S. Food and Drug Administration...

Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026

China’s National Healthcare Security Administration (NHSA) announced that the application period for the 2026 adjustment...

Company Drug

Simcere Pharmaceutical Secures NMPA Approval for SIM0689 Bispecific Antibody Targeting PD-1 and VEGF in Solid Tumors

Fineline Cube Jun 15, 2026

Simcere Pharmaceutical Group (HKG: 2096) announced that SIM0689, a novel bispecific antibody (BsAb) targeting both...

Company Drug

Mabwell Bioscience Secures FDA Approval for 6MW5311 Bispecific Antibody Trial in Hematologic Malignancies

Fineline Cube Jun 15, 2026

Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) announced that the U.S. Food and Drug Administration...

Company Deals

Qingfeng Pharmaceutical Group Partners with TASCO PHARMA to Commercialize Anti-Tumor and CNS Medicines in Vietnam

Fineline Cube Jun 15, 2026

Qingfeng Pharmaceutical Group announced a strategic commercialization cooperation agreement with Vietnam’s TASCO PHARMA for the...

Posts pagination

1 … 27 28 29 … 710

Recent updates

  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
  • Ascentage Pharma 1H 2026: Revenue Jumps 29% to RMB 302 Million as Olverembatinib and Lisaftoclax Power Commercial Growth
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.